{"url_path":"/sec/dbvt/8-k/2026-06-29/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1613780/0001193125-26-288533-index.html","accession_number":"0001193125-26-288533","cik":"0001613780","ticker":"DBVT","issuer_name":"DBV Technologies S.A.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1613780/0001193125-26-288533-index.html","primary_entity_key":"0001613780","primary_entity_name":"DBV Technologies S.A."},"word_count":71,"has_tables":true,"body_markdown":"Item 8.01.\n\nOther Events\n\nOn June 29, 2026, DBV Technologies S.A. (the “Company”) issued a press release entitled “DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 Through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference."}